The department makes prior approval and Preferred Drug List (PDL) decisions in consultation with the Illinois State Medical Society Committee on Drugs and Therapeutics (D and T Committee). The D and T Committee is comprised of practicing physicians representing various specialties who actively participate in the Illinois Medicaid Program. The Committee makes recommendations based upon evidence-based clinical factors including safety, effectiveness and outcomes.
At its meetings, the D and T Committee 1) reviews new pharmaceutical products and makes prior approval recommendations; 2) considers manufacturer appeals of previous prior approval and PDL recommendations; and 3) reviews the department’s recommendations for PDL classes under review
You can view a list of PDL Classes under review for the upcoming D and T meeting.
D and T Agenda 2019
D and T Meeting Results 2019
Archived D and T Meeting Results
Archived D and T Agenda
New pharmaceutical products will require prior approval upon entry into the market. To request that the Committee on Drugs and Therapeutics review a new product, manufacturers should complete the D and T Committee Agenda Request Form. At the time the manufacturer requests review, they may also submit an offer of supplemental rebates to the Department by completing and submitting the offer form. Instructions for submission of the offer form are included within the offer form.
Manufacturers wishing to appeal a decision on the status of their products with respect to prior approval or preferred drug list should complete the D and T Committee Agenda Request Form. At the time the manufacturer requests the appeal, they may also submit an offer of supplemental rebates to the Department by completing and submitting the offer form. Instructions for submission of the offer form are included within the offer form.
Drugs and Therapeutics Committee (D and T Committee) Agenda Request
Instructions for Submission of Clinical Information
Manufacturers whose products are being reviewed may submit clinical information to the Drugs and Therapeutics (D and T) Committee and the Department. Manufacturers should submit a concise synopsis of their product. This synopsis should be no more than four pages in length. The Committee is particularly interested in information that sets a drug apart from other drugs in its class or PDL category. The Committee is not interested in materials intended to market a product. For information on the process for submitting clinical information to the D and T Committee, manufacturers should contact Ken Ryan at the Illinois State Medical Society. Clinical information may also be submitted to the department’s clinical contractor at:
Mary Lynn Moody, BSPharm
Director, Drug Information Center
Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois at Chicago
College of Pharmacy
833 S. Wood Street
Chicago, Il 60611